drugset / Trial / NCT05017610
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
NaSingle-groupOpen-labelTreatment
Summary
This early phase I trial studies the safety and feasibility of inducing a hypothyroxinemic state in patients with glioblastoma or gliosarcoma that has come back (recurrent). This trial aims to see if giving a specific thyroid hormone, such as methimazole and liothyronine, is safe and could benefit cancer treatment.
Timeline
- Start
- 2021-10-20
- Primary completion
- 2022-10-14
- Completion
- 2022-10-14
Outcome
Outcome not reported
Stopped (Enrollment): “Per the PI-slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liothyronine | Unknown | — | Oral |
| Subject | Lomustine | Small molecule | — | Oral |
| Subject | Methimazole | Small molecule | — | Oral |